Tumor treating fields: a new frontier in cancer therapy

Davies, Angela M.; Weinberg, Uri; Palti, Yoram

doi:10.1111/nyas.12112

Cited by 163 publications

(151 citation statements)

References 31 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Even longer-term effects of TTFields may be reported in the future. Patients have tolerated TTFields well, as demonstrated by the high average compliance observed (8,9,19,43).…”

Section: Toxicity Profilementioning

confidence: 99%

“…The most common adverse event related to TTFields is mild-to-moderate dermatitis (of either contact or allergic etiology) at the site of the transducer array placement (8,9,42). In recurrent-and newly diagnosed GBM patients, the frequency of this adverse event was 16% and 43% of TTFields-treated patients, respectively.…”

Section: Toxicity Profilementioning

confidence: 99%

“…Under a uniform alternating electric field, any charged molecule will oscillate in an attempt to align itself appropriately parallel to the direction of the electric force vector it is exposed to (14). Key macromolecules and organelles responsible for mitosis and cytokinesis are highly polar, and their random movement, which is critical for their function, can be disrupted by the application of localized electric fields (9,(17)(18)(19).…”

Section: Biophysics Of Ttfieldsmentioning

confidence: 99%

“…TTFields selectively disrupt cell division, and preclinical research has demonstrated the antimitotic effects of TTFields in different tumor types (3)(4)(5)(6). TTFields have been found to prolong survival in patients with glioblastoma multiforme (GBM), which led to its approval by the FDA for recurrent and newly diagnosed GBM after surgery and radiotherapy with adjuvant temozolomide (7)(8)(9)(10)(11). In addition, this treatment modality has been recognized by the American Society of Clinical Oncology (ASCO) as an advancement in cancer treatment due to its novel approach, effectiveness, and low toxicity profile (12).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

Self Cite

275

181

View full text Add to dashboard Cite

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266-75. Ó2017 AACR.

show abstract

“…Even longer-term effects of TTFields may be reported in the future. Patients have tolerated TTFields well, as demonstrated by the high average compliance observed (8,9,19,43).…”

Section: Toxicity Profilementioning

confidence: 99%

Section: Toxicity Profilementioning

confidence: 99%

Section: Biophysics Of Ttfieldsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

Self Cite

275

181

View full text Add to dashboard Cite

show abstract

“…Researchers wait for improving results from these trials same as newly diagnosed or recurrent glioblastoma [18,19].…”

Section: Indications Contraindicationsmentioning

confidence: 99%

Tumor treating fields for glioblastoma: Review

Uysal¹

2017

Neurol Disord Therap

View full text Add to dashboard Cite

Tumor treating fields (TTF) is delivered with an original device causing antimitotic activity in tumor cells of glioblastoma patients. Low intensity and intermediate frequency alternating electric fields are effective over metaphase. Tumor treating fields is a novel modality approved by FDA (Federal Drug Association) for newly diagnosed and also recurrent glioblastoma. Frequency of 200 kHz is given with transducer applied on scalp of patient. Phase 3 trial showed the efficacy of this modality alone equivalent compared to chemotherapy. Skin toxicity is the major side effect of this therapy. TTF is now used in recurrent glioblastoma but future perspective shows that this unique modality can be delivered in different solid tumors.

show abstract

Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches

Yeini

Ofek

Albeck

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Glioblastoma (GB) is the most lethal type of primary tumor in the central nervous system. Current treatments include surgical resection followed by chemotherapy and radiotherapy. With this therapeutic regimen, the median survival is less than two years. However, these treatments do not much improve the overall survival of GB patients. GBs are highly angiogenic and invasive tumors and often acquire resistance to therapy. The invasive nature of the disease limits the ability to achieve complete resection of the tumor and the majority of GB patients will experience disease relapse. Moreover, GB is highly heterogeneous, harboring different mutations and presenting different phenotypes. As the brain is considered to be an immune‐privileged tissue, GB is defined as a cold tumor for which current immunotherapies have not yet been demonstrated to improve survival. On top of these challenges, the blood brain barrier (BBB) restricts the uptake of drugs by the brain, thus limiting the therapeutic options. Therefore, enormous efforts are being dedicated to the development of novel nanomedicines, which will be able to cross the BBB and specifically target the cancer cells. Here, the current achievements in drug delivery and novel therapeutic approaches for GB therapy are discussed.

show abstract

Tumor treating fields: a new frontier in cancer therapy

Cited by 163 publications

References 31 publications

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Tumor treating fields for glioblastoma: Review

Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches

Contact Info

Product

Resources

About